Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | APAF1 | O14727 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204329 | 0.88 | ROCK2 (0.54) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL29039315 | 0.80 | NOS1 (0.49) | MAPTKDM4EMEN1KMT2AAPAF1 | |
| SCHEMBL30385421 | 0.80 | NOS1 (0.49) | MAPTKDM4EMEN1KMT2AAPAF1 | |
| SCHEMBL30837522 | 0.79 | NOS1 (0.52) | MAPTKDM4EMEN1KMT2ANOS1 | |
| SCHEMBL30469212 | 0.78 | TERT (0.53) | MAPTKDM4EMEN1KMT2AAPAF1 | |
| SCHEMBL15515585 | 0.78 | ROCK2 (0.51) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL18399080 | 0.77 | ABL1 (0.48) | MAPTKDM4EMEN1KMT2AAPAF1 | |
| SCHEMBL5094880 | 0.76 | HTR6 (0.45) | MAPTKDM4EMEN1KMT2AAPAF1 | |
| SCHEMBL4590692 | 0.74 | ALDH1A1 (0.47) | MAPTKDM4EMEN1KMT2AAPAF1 | |
| SCHEMBL18399012 | 0.74 | SYK (0.59) | MAPTKDM4EMEN1KMT2ANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | MAPT 4124/4885KDM4E 876/4885MEN1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.